Learn the Latest for High-Risk Breast Cancer Patients Register Today

The gold-standard HRD test1 now validated for local laboratories

Download the clinical summary

Denkert clinical summary screenshot_locked

References

  1. Miller, R.E. et al. “ESMO Recommendations On Predictive Biomarker Testing For Homologous Recombination Deficiency And PARP Inhibitor Benefit In Ovarian Cancer”. Annals Of Oncology, vol 31, no. 12, 2020, pp. 1606-1622.